NCT00080457已完成3 期
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Sitaxsentan Sodium (Thelin™) Treatment With an Open-Label Bosentan Arm in Patients With Pulmonary Arterial Hypertension (PAH)
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 240
- 试验地点
- 2
研究概览
简要总结
The purpose of this study is to evaluate the safety and efficacy of Thelin™ (sitaxsentan sodium) compared to placebo (sugar pill) in the treatment of patients with pulmonary arterial hypertension (PAH).
详细描述
The purpose of this study is to evaluate the safety and efficacy of Thelin™ (sitaxsentan sodium) as compared to placebo in the treatment of patients with PAH. A cohort of patients will be randomized to usual treatment with Tracleer® (bosentan) for observational comparisons of safety and efficacy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 12 Years 至 75 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have a current diagnosis of symptomatic PAH classified by one of the following:
- •primary pulmonary hypertension (PPH) - also known as idiopathic pulmonary arterial hypertension (IPAH);
- •PAH associated with connective tissue diseases;
- •PAH associated with one of the following congenital heart defects:
- •repaired ASD, VSD or PDA greater than one year post-operative
- •un-repaired secundum ASD (with resting oxygen saturation greater than 88 percent in room air measured by oximeter)
- •World Health Organization (WHO) functional class II, III, IV
- •Greater than 12 and less than 75 years of age
- •Women of childbearing potential must be using two forms of medically acceptable contraception (at least one barrier method)
- •Have a cardiac catheterization within 6 months before study entry that shows the following values:
- •mean pulmonary artery pressure (PAPm) greater than 25 mmHg (at rest),
- •pulmonary capillary wedge pressure (PCWP) or left ventricular-end diastolic pressure less than 15 mmHg, and
- •pulmonary vascular resistance (PVR) greater than 3 mmHg/L/min.
排除标准
- •Portal hypertension or chronic liver disease
- •ALT or AST levels greater than 1.5 times the upper limit of normal at the Screening Visit
- •Contraindication to treatment with an endothelin receptor antagonist
- •Recent history of abusing alcohol or illicit drugs
- •Chronic renal insufficiency
- •Pregnant or breastfeeding
- •Atrial septostomy within 30 days before study entry
- •Previous failure on bosentan because of safety concerns of the lack of clinical response
研究者
研究点 (2)
Loading locations...
相似试验
招募中
3 期
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)Generalized Myasthenia GravisNCT06456580Vor Biopharma180
已完成
3 期
A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)Type 2 Diabetes MellitusNCT01076075Merck Sharp & Dohme LLC427
已完成
2 期
Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)Glucose IntoleranceNCT01405911Merck Sharp & Dohme LLC242
已完成
3 期
Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)Type 2 Diabetes MellitusNCT00541775Merck Sharp & Dohme LLC273
已完成
2 期
A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)Type 2 Diabetes MellitusNCT00127192Merck Sharp & Dohme LLC363